Press release from Companies
Publicerat: 2025-05-13 17:40:00
Correction of the press release published on 7 May 2025 regarding the resolution from the extraordinary general meeting on 7 January 2025 on the reduction of share capital and reverse share split where the registered share capital was incorrect. The correct share capital and number of shares are stated below.
Shares and share capital
The board's decision thus means that the registered share capital continues to amount to SEK 42,952,081.9244 divided into 9,337,409,114 shares, each share with a quota value of SEK 0.0046.
For further information please contact:
Anna Linton, CEO of Peptonic Medical AB
E-mail: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
